A user's guide for α-synuclein biomarker studies in biological fluids

Perianalytical considerations

for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α-synuclein and antibody-independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α-synuclein levels in the clinical setting.

Original languageEnglish
Pages (from-to)1117-1130
Number of pages14
JournalMovement Disorders
Volume32
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

Synucleins
Parkinson Disease
Biomarkers
Post Translational Protein Processing
Practice Guidelines
Immunoassay
Detergents
Freezing
Disease Progression
Comorbidity
Guidelines
Phenotype
Temperature
Antibodies
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • Biomarker
  • cerebrospinal fluid
  • diagnostics
  • Parkinson's disease
  • standard operating procedures
  • α-synuclein

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research (2017). A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders, 32(8), 1117-1130. https://doi.org/10.1002/mds.27090

A user's guide for α-synuclein biomarker studies in biological fluids : Perianalytical considerations. / for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research.

In: Movement Disorders, Vol. 32, No. 8, 01.08.2017, p. 1117-1130.

Research output: Contribution to journalReview article

for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research 2017, 'A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations', Movement Disorders, vol. 32, no. 8, pp. 1117-1130. https://doi.org/10.1002/mds.27090
for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research. A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders. 2017 Aug 1;32(8):1117-1130. https://doi.org/10.1002/mds.27090
for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research. / A user's guide for α-synuclein biomarker studies in biological fluids : Perianalytical considerations. In: Movement Disorders. 2017 ; Vol. 32, No. 8. pp. 1117-1130.
@article{8a2d2526a5464fe0a4612651ab129eaa,
title = "A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations",
abstract = "Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α-synuclein and antibody-independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α-synuclein levels in the clinical setting.",
keywords = "Biomarker, cerebrospinal fluid, diagnostics, Parkinson's disease, standard operating procedures, α-synuclein",
author = "{for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research} and Brit Mollenhauer and Richard Batrla and {Ali El-Agnaf}, Omar and Galasko, {Douglas R.} and Lashuel, {Hilal A.} and Merchant, {Kalpana M.} and Shaw, {Lesley M.} and Selkoe, {Dennis J.} and Robert Umek and Hugo Vanderstichele and Henrik Zetterberg and Jing Zhang and Chelsea Caspell-Garcia and Chris Coffey and Hutten, {Samantha J.} and Mark Frasier and Peggy Taylor and Robert Umek and Dennis Selkoe and Brit Mollenhauer and Henrik Zetterberg and {Du Bowman}, Bois and Hugo Vanderstichele and Peggy Taylor and Omar El-Agnaf and Jing Zhang and Lashuel, {Hial A.} and Bradley Hyman and Peter Juhasz and Michael Ahlijanian and Andreas Jeromin and Laura Parkkinen and Claudio Soto and Steven Lee and Andrea Caricasole and Lara Petricca and Katrina Paumier and Martin Latterich and {Henning Jensen}, Poul and Kalpana Merchant and John Hale and Richard Batrla and Armin Giese and Thomas Pochapsky and Paul Kotzbauer and Tim Bartels and Clemens Scherzer and Niels Kruse and Erik Stoops and Adrian Schmid",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/mds.27090",
language = "English",
volume = "32",
pages = "1117--1130",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - A user's guide for α-synuclein biomarker studies in biological fluids

T2 - Perianalytical considerations

AU - for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research

AU - Mollenhauer, Brit

AU - Batrla, Richard

AU - Ali El-Agnaf, Omar

AU - Galasko, Douglas R.

AU - Lashuel, Hilal A.

AU - Merchant, Kalpana M.

AU - Shaw, Lesley M.

AU - Selkoe, Dennis J.

AU - Umek, Robert

AU - Vanderstichele, Hugo

AU - Zetterberg, Henrik

AU - Zhang, Jing

AU - Caspell-Garcia, Chelsea

AU - Coffey, Chris

AU - Hutten, Samantha J.

AU - Frasier, Mark

AU - Taylor, Peggy

AU - Umek, Robert

AU - Selkoe, Dennis

AU - Mollenhauer, Brit

AU - Zetterberg, Henrik

AU - Du Bowman, Bois

AU - Vanderstichele, Hugo

AU - Taylor, Peggy

AU - El-Agnaf, Omar

AU - Zhang, Jing

AU - Lashuel, Hial A.

AU - Hyman, Bradley

AU - Juhasz, Peter

AU - Ahlijanian, Michael

AU - Jeromin, Andreas

AU - Parkkinen, Laura

AU - Soto, Claudio

AU - Lee, Steven

AU - Caricasole, Andrea

AU - Petricca, Lara

AU - Paumier, Katrina

AU - Latterich, Martin

AU - Henning Jensen, Poul

AU - Merchant, Kalpana

AU - Hale, John

AU - Batrla, Richard

AU - Giese, Armin

AU - Pochapsky, Thomas

AU - Kotzbauer, Paul

AU - Bartels, Tim

AU - Scherzer, Clemens

AU - Kruse, Niels

AU - Stoops, Erik

AU - Schmid, Adrian

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α-synuclein and antibody-independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α-synuclein levels in the clinical setting.

AB - Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids. Current knowledge and pitfalls are discussed, and selected perianalytical variables are presented systematically, including different temperature of sample collection and types of collection tubes, gradient sampling, the addition of detergent, aliquot volume, the freezing time, and the different thawing methods. We also discuss analytical confounders. We identify gaps in the knowledge and delineate specific areas that require further investigation, such as the need to identify posttranslational modifications of α-synuclein and antibody-independent reference methods for quantification, as well as the analysis of potential confounders, such as comorbidities, medication, and phenotypes of Parkinson's disease in larger cohorts. This review could be used as a guideline for future Parkinson's disease biomarker studies and will require regular updating as more information arises in this growing field, including new technical developments as they become available. In addition to reviewing best practices, we also identify the current technical limitations and gaps in the knowledge that should be addressed to enable accurate and quantitative assessment of α-synuclein levels in the clinical setting.

KW - Biomarker

KW - cerebrospinal fluid

KW - diagnostics

KW - Parkinson's disease

KW - standard operating procedures

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85028058287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028058287&partnerID=8YFLogxK

U2 - 10.1002/mds.27090

DO - 10.1002/mds.27090

M3 - Review article

VL - 32

SP - 1117

EP - 1130

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -